303 related articles for article (PubMed ID: 18451150)
1. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors.
Shafee N; Smith CR; Wei S; Kim Y; Mills GB; Hortobagyi GN; Stanbridge EJ; Lee EY
Cancer Res; 2008 May; 68(9):3243-50. PubMed ID: 18451150
[TBL] [Abstract][Full Text] [Related]
2. Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo.
Pajic M; Kersbergen A; van Diepen F; Pfauth A; Jonkers J; Borst P; Rottenberg S
Cell Cycle; 2010 Sep; 9(18):3780-91. PubMed ID: 20855963
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
Zander SA; Kersbergen A; van der Burg E; de Water N; van Tellingen O; Gunnarsdottir S; Jaspers JE; Pajic M; Nygren AO; Jonkers J; Borst P; Rottenberg S
Cancer Res; 2010 Feb; 70(4):1700-10. PubMed ID: 20145144
[TBL] [Abstract][Full Text] [Related]
4. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Rottenberg S; Jaspers JE; Kersbergen A; van der Burg E; Nygren AO; Zander SA; Derksen PW; de Bruin M; Zevenhoven J; Lau A; Boulter R; Cranston A; O'Connor MJ; Martin NM; Borst P; Jonkers J
Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17079-84. PubMed ID: 18971340
[TBL] [Abstract][Full Text] [Related]
5. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.
Rottenberg S; Nygren AO; Pajic M; van Leeuwen FW; van der Heijden I; van de Wetering K; Liu X; de Visser KE; Gilhuijs KG; van Tellingen O; Schouten JP; Jonkers J; Borst P
Proc Natl Acad Sci U S A; 2007 Jul; 104(29):12117-22. PubMed ID: 17626183
[TBL] [Abstract][Full Text] [Related]
6. Selected Alkylating Agents Can Overcome Drug Tolerance of G
Pajic M; Blatter S; Guyader C; Gonggrijp M; Kersbergen A; Küçükosmanoğlu A; Sol W; Drost R; Jonkers J; Borst P; Rottenberg S
Clin Cancer Res; 2017 Nov; 23(22):7020-7033. PubMed ID: 28821557
[No Abstract] [Full Text] [Related]
7. BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
Drost R; Dhillon KK; van der Gulden H; van der Heijden I; Brandsma I; Cruz C; Chondronasiou D; Castroviejo-Bermejo M; Boon U; Schut E; van der Burg E; Wientjens E; Pieterse M; Klijn C; Klarenbeek S; Loayza-Puch F; Elkon R; van Deemter L; Rottenberg S; van de Ven M; Dekkers DH; Demmers JA; van Gent DC; Agami R; Balmaña J; Serra V; Taniguchi T; Bouwman P; Jonkers J
J Clin Invest; 2016 Aug; 126(8):2903-18. PubMed ID: 27454287
[TBL] [Abstract][Full Text] [Related]
8. EZH2 Is Overexpressed in
Puppe J; Opdam M; Schouten PC; Jóźwiak K; Lips E; Severson T; van de Ven M; Brambillasca C; Bouwman P; van Tellingen O; Bernards R; Wesseling J; Eichler C; Thangarajah F; Malter W; Pandey GK; Ozretić L; Caldas C; van Lohuizen M; Hauptmann M; Rhiem K; Hahnen E; Reinhardt HC; Büttner R; Mallmann P; Schömig-Markiefka B; Schmutzler R; Linn S; Jonkers J
Clin Cancer Res; 2019 Jul; 25(14):4351-4362. PubMed ID: 31036541
[TBL] [Abstract][Full Text] [Related]
9. TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.
Erriquez J; Becco P; Olivero M; Ponzone R; Maggiorotto F; Ferrero A; Scalzo MS; Canuto EM; Sapino A; Verdun di Cantogno L; Bruna P; Aglietta M; Di Renzo MF; Valabrega G
Gynecol Oncol; 2015 Sep; 138(3):627-33. PubMed ID: 26100858
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
van de Ven M; van der Burg E; van der Gulden H; Klarenbeek S; Bouwman P; Jonkers J
J Pathol; 2017 Mar; 241(4):511-521. PubMed ID: 27943283
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.
Evers B; Drost R; Schut E; de Bruin M; van der Burg E; Derksen PW; Holstege H; Liu X; van Drunen E; Beverloo HB; Smith GC; Martin NM; Lau A; O'Connor MJ; Jonkers J
Clin Cancer Res; 2008 Jun; 14(12):3916-25. PubMed ID: 18559613
[TBL] [Abstract][Full Text] [Related]
12. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice.
Brodie SG; Xu X; Qiao W; Li WM; Cao L; Deng CX
Oncogene; 2001 Nov; 20(51):7514-23. PubMed ID: 11709723
[TBL] [Abstract][Full Text] [Related]
13. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
14. Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance.
Warmoes M; Jaspers JE; Xu G; Sampadi BK; Pham TV; Knol JC; Piersma SR; Boven E; Jonkers J; Rottenberg S; Jimenez CR
Mol Cell Proteomics; 2013 May; 12(5):1319-34. PubMed ID: 23397111
[TBL] [Abstract][Full Text] [Related]
15. How do real tumors become resistant to cisplatin?
Borst P; Rottenberg S; Jonkers J
Cell Cycle; 2008 May; 7(10):1353-9. PubMed ID: 18418074
[TBL] [Abstract][Full Text] [Related]
16. Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.
Raguz S; Adams C; Masrour N; Rasul S; Papoutsoglou P; Hu Y; Cazzanelli G; Zhou Y; Patel N; Coombes C; Yagüe E
Biochem Pharmacol; 2013 Jan; 85(2):186-96. PubMed ID: 23122841
[TBL] [Abstract][Full Text] [Related]
17. EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.
Zander SA; Sol W; Greenberger L; Zhang Y; van Tellingen O; Jonkers J; Borst P; Rottenberg S
PLoS One; 2012; 7(9):e45248. PubMed ID: 23028879
[TBL] [Abstract][Full Text] [Related]
18. Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation.
Bai F; Smith MD; Chan HL; Pei XH
Oncogene; 2013 May; 32(22):2715-25. PubMed ID: 22777348
[TBL] [Abstract][Full Text] [Related]
19. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.
Bertolini G; Roz L; Perego P; Tortoreto M; Fontanella E; Gatti L; Pratesi G; Fabbri A; Andriani F; Tinelli S; Roz E; Caserini R; Lo Vullo S; Camerini T; Mariani L; Delia D; Calabrò E; Pastorino U; Sozzi G
Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16281-6. PubMed ID: 19805294
[TBL] [Abstract][Full Text] [Related]
20. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin.
Bhattacharyya A; Ear US; Koller BH; Weichselbaum RR; Bishop DK
J Biol Chem; 2000 Aug; 275(31):23899-903. PubMed ID: 10843985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
